HighTower Advisors’s Tandem Diabetes Care TNDM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-121,460
Closed -$2.26M 4059
2025
Q2
$2.26M Buy
121,460
+54,292
+81% +$1.08M ﹤0.01% 1502
2025
Q1
$1.29M Buy
67,168
+57,635
+605% +$1.69M ﹤0.01% 1795
2024
Q4
$343K Buy
+9,533
New +$322K ﹤0.01% 2778
2022
Q4
Sell
-4,209
Closed -$202K 3518
2022
Q3
$202K Sell
4,209
-99
-2% -$5.43K ﹤0.01% 2601
2022
Q2
$255K Sell
4,308
-3,479
-45% -$286K ﹤0.01% 2465
2022
Q1
$900K Sell
7,787
-408
-5% -$47.6K ﹤0.01% 1820
2021
Q4
$1.24M Buy
8,195
+1,570
+24% +$212K ﹤0.01% 1650
2021
Q3
$783K Buy
6,625
+1,969
+42% +$217K ﹤0.01% 1793
2021
Q2
$453K Buy
4,656
+88
+2% +$7.85K ﹤0.01% 2109
2021
Q1
$403K Buy
4,568
+594
+15% +$55.2K ﹤0.01% 2118
2020
Q4
$384K Buy
3,974
+1,048
+36% +$108K ﹤0.01% 1774
2020
Q3
$333K Buy
2,926
+110
+4% +$11.6K ﹤0.01% 1772
2020
Q2
$280K Sell
2,816
-215
-7% -$17.2K ﹤0.01% 1787
2020
Q1
$193K Buy
+3,031
New +$212K ﹤0.01% 1801
2019
Q2
Sell
-5,693
Closed -$350K 2511
2019
Q1
$350K Buy
+5,693
New +$299K ﹤0.01% 1650
2015
Q2
Sell
-10,063
Closed -$4.1M 1721
2015
Q1
$4.1M Buy
+10,063
New +$1.31M 0.06% 351

Other funds holding TNDM

HighTower Advisors's TNDM Position: Q3 2025 in Review

HighTower Advisors sold out of Tandem Diabetes Care (TNDM) in Q3 2025, closing a stake of 121,460 shares — an estimated $2.26M sold.

HighTower Advisors first reported a position in TNDM in Q1 2015 and held it in 16 quarters. The position peaked at $4.1M in Q1 2015. 255 funds tracked by Wall St. Rank hold TNDM as of Q3 2025.

  • HighTower Advisors reported no remaining Tandem Diabetes Care position as of Q3 2025 after selling out during the quarter.
  • HighTower Advisors sold 121,460 Tandem Diabetes Care shares in Q3 2025, an estimated $2.26M.
  • HighTower Advisors first reported a position in Tandem Diabetes Care in Q1 2015 and held it in 16 quarters.
  • HighTower Advisors's Tandem Diabetes Care position peaked at $4.1M in Q1 2015.
  • 255 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q3 2025.

Based on HighTower Advisors's 13F filing for Q3 2025, filed 7 Nov 2025.